Buenos Aires , Argentina; Research Site:
A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
Córdoba, Argentina; Research Site:
A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
La Plata, Argentina; Research Site:
A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
Pilar, Argentina; Research Site:
A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
Rosario, Argentina; Research Site:
A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
Adelaide, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Brisbane, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Fitzroy, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Frankston, Australia; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Frankston, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Fremantle, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Geelong, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Gosford, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Liverpool, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Melbourne, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Melbourne, Australia; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Newcastle, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Perth, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
St. Leonards, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Sydney, Australia; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Sydney, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Waratah, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Wodonga, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Woolloongabba, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bludesch, Austria; Research Site:
CHAIROS study A Study of MabThera (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
Innsbruck, Austria; Research Site:
CHAIROS study A Study of MabThera (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
Leoben, Austria; Research Site:
CHAIROS study A Study of MabThera (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
Leoben, Austria; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Linz, Austria; Research Site:
CHAIROS study A Study of MabThera (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
Salzburg, Austria; Research Site:
CHAIROS study A Study of MabThera (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
Wels, Austria; Research Site:
CHAIROS study A Study of MabThera (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
Wien, Austria; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Antwerpen, Belgium; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Brugge, Belgium; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bruxelles, Belgium; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Bruxelles, Belgium; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Edegem, Belgium; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Leuven, Belgium; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Leuven, Belgium; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Mont-Godinne, Belgium; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Edmonton, AB, Canada; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Halifax, NS, Canada; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Ottawa, ON, Canada; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
St John'S, Canada; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Toronto, ON, Canada; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Vancouver, BC, Canada; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Brno, Czech Republic; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Hradec Kralove, Czech Republic; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Olomouc, Czech Republic; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Plzen, Czech Republic; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Praha, Czech Republic; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Aalborg, Denmark; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Århus, Denmark; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Herlev, Denmark; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
København, Denmark; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Vejle, Denmark; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bordeaux, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Caen, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Clermont-Ferrand, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Colmar, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Creteil, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Le Chesnay, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Le Mans, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Le Mans, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Lille, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Lille, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Limoges, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Lyon, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Lyon, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Marseille, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Marseille, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Montpellier, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Montpellier, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Nantes, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Paris, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Paris, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Pierre Benite, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Rennes, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Rouen, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Saint-Priest-En-Jarez, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Strasbourg, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Toulouse, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Tours, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Vandoeuvre-Les-Nancy, France; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Ahaus, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Ansbach, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Augsburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bad Saarow, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bayreuth, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Berlin, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bielefeld, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bietigheim-Bissingen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bochum, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bottrop, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bremen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Burglengenfeld, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Coesfeld, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Cottbus, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Dresden, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Düsseldorf, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Eisenach, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Erfurt, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Erfurt, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination Chemotherapy in Patients With B-Cell Chronic Lymphocytic Leukemia
Erlangen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Eschweiler, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Essen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Esslingen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Forchheim, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Frankfurt Am Main, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Frankfurt Am Oder, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Freiburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Garmisch-Partenkirchen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Gerlingen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Giessen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Göttingen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Greifswald, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Grenzach-Wyhlen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination Chemotherapy in Patients With B-Cell Chronic Lymphocytic Leukemia
Hagen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Halle, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Hamburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Hamm, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Hannover, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Heidelberg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination Chemotherapy in Patients With B-Cell Chronic Lymphocytic Leukemia
Heidelberg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Herne, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Herrsching, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Homburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Idar-Oberstein, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Jena, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Karlsruhe, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Kassel, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Kempten, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Kiel, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Koblenz, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Köln, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Köln, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination Chemotherapy in Patients With B-Cell Chronic Lymphocytic Leukemia
Kronach, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Landshut, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Leer, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Leipzig, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Lemgo, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Lörrach, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Lübeck, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Ludwigshafen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Magdeburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Mainz, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Mannheim, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
München, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Münchengladbach, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Münster, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Neunkirchen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Nordenstedt, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Nürnberg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Oberhausen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Offenbach, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Oldenburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Pasewalk, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Pforzheim, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Potsdam, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Recklinghausen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Regensburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Rostock, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Saarbrücken, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Sande, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Siegen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Stuttgart, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination Chemotherapy in Patients With B-Cell Chronic Lymphocytic Leukemia
Stuttgart, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Torgau, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Trier, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Troisdorf, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Tübingen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Ulm, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Villingen-Schwenningen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Wanzleben, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Weiden, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Wesel, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Wiesbaden, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Wuppertal, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Würzburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Budapest, Hungary; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Debrecen, Hungary; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Pecs, Hungary; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Szeged, Hungary; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Beer Sheva, Israel; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Haifa, Israel; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Jerusalem, Israel; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Kfar Saba, Israel; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Petah Tikva, Israel; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Ramat Gan, Israel; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Rehovot, Israel; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bari, Italy; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Bologna, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Bologna, Italy; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Cagliari, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Genova, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Milano, Italy; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Milano, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Napoli, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Napoli, Italy; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Pavia, Italy; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Pavia, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Roma, Italy; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Roma, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Roma, Italy; Research Site:
A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL) Responsive to First Line Therapy
Siena, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Torino, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Verona, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Vicenza, Italy; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Vicenza, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Amersfoort, Netherlands; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Amsterdam, Netherlands; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Den Haag, Netherlands; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Rotterdam, Netherlands; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Auckland, New Zealand; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Auckland, New Zealand; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Christchurch, New Zealand; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Christchurch, New Zealand; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Palmerston North, New Zealand; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Wellington, New Zealand; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Oslo, Norway; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Lodz, Poland; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Lublin, Poland; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Warszawa, Poland; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Bucharest, Romania; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Targu-Mures, Romania; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Timisoara, Romania; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Moscow, Russian Federation; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Obninsk, Russian Federation; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Samara, Russian Federation; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
St Petersburg, Russian Federation; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Alcala De Henares, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Alcorcon, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Badajoz, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Bilbao, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Caceres, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Cádiz, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Castellon, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Fuenlabrada, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Gandia, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Granada, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Hospitalet de Llobregat, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Jerez De La Frontera, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
La Coruna, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Madrid, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Madrid, Spain; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Madrid, Spain; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Malaga, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Malaga, Spain; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Mostoles, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Murcia, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Murcia, Spain; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Sagunto, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Salamanca, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Salamanca, Spain; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Santander, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Toledo, Spain; Research Site:
A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Valencia, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Vitoria, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Zaragoza, Spain; Research Site:
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Zaragoza, Spain; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Huddinge, Sweden; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Linkoeping, Sweden; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Birmingham, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Bournemouth, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Bournemouth, United Kingdom; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Cambridge, United Kingdom; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Cambridge, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Canterbury, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Glasgow, United Kingdom; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Hull, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Leeds, United Kingdom; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Leeds, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Leicester, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Liverpool, United Kingdom; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Liverpool, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
London, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
London, United Kingdom; Research Site:
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Sutton, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Wakefield, United Kingdom; Research Site:
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Caracas, Venezuela; Research Site:
A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
